Merck's Keytruda Wins European Approval For Post-Surgery Kidney Cancer

The European Commission has approved Merck & Co Inc's MRK Keytruda as monotherapy for the adjuvant treatment of adults with renal cell carcinoma (RCC).

  • Renal cell carcinoma is the most common type of kidney cancer; about nine out of 10 kidney cancer diagnoses are RCCs. 
  • The approval covers patients at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. 
  • This approval is based on results from the Phase 3 KEYNOTE-564 trial. Keytruda demonstrated a statistically significant improvement in disease-free survival (DFS), reducing the risk of disease recurrence or death by 32% compared to placebo.
  • Price Action: MRK shares are down 0.11% at $79.05 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsrenal cell carcinoma
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!